Loading...

BrightPath Biotherapeutics Co., Ltd.

4594.T•JPX
Healthcare
Biotechnology
¥64.00
¥-3.00(-4.48%)

BrightPath Biotherapeutics Co., Ltd. (4594.T) Stock Overview

Explore BrightPath Biotherapeutics Co., Ltd.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 64.8/100

Key Financials

Market Cap8B
P/E Ratio-4.88
EPS (TTM)$-14.12
ROE-1.16%
Fundamental Analysis

AI Price Forecasts

1 Week$38.61
1 Month$36.83
3 Months$36.77
1 Year Target$30.59

4594.T Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of BrightPath Biotherapeutics Co., Ltd. (4594.T) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 57.40, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $30.59.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -4.88 and a market capitalization of 8B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

57.40RSI (14)
7.47MACD
61.24ADX
Stats data is not available for 4594.TStats details for 4594.T are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for 4594.TAnalyst Recommendations details for 4594.T are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

BrightPath Biotherapeutics Co., Ltd. develops cancer immunotherapy drugs. The company is developing GRN-1201 that is in Phase II clinical study for the treatment of non-small cell lung cancer, as well as in Phase I clinical study to treat melanoma. It also develops BP1101, a neoantigen vaccine; BP1209, a platform of personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. In addition, the company offers induced pluripotent stem cell derived regenerated NKT cell therapy for head and neck cancer; and BP2301, an autologous HER2 chimeric antigen receptor-T cell therapy for treating solid tumors sarcoma. Further, it is involved in discovering BP1200, an antibody targeting CD73; BP1210, an immune checkpoint inhibitory antibody; and other antibodies, such as BP1202, BP1206, and BP1211. The company was formerly known as GreenPeptide Co., Ltd. and changed its name to BrightPath Biotherapeutics Co., Ltd. in July 2017. BrightPath Biotherapeutics Co., Ltd. was founded in 2003 and is headquartered in Tokyo, Japan.

CEO

Kenichi Nagai

Employees

42

Headquarters

Kojimachi Central Building, Tokyo

Founded

2015

Frequently Asked Questions

;